Sponsor
We gratefully acknowledge financial support from the M. J. Murdock Charitable Trust (FSU-202118942), the National Science Foundation (CHE-2319929), and Reed College (startup, Stillman Drake and summer funds).
Published In
Rsc Pharmaceutics
Document Type
Article
Publication Date
12-10-2024
Subjects
Antimicrobial combination therapies
Abstract
A clinically relevant multidrug solid comprising sulbactam (β-lactamase inhibitor) and amantadine (antiviral) displays enhanced thermal stability and sustained antibacterial activity compared to starting materials.
We describe the formation of a multidrug salt comprising sulbactam (SUL, β-lactamase inhibitor) and amantadine (AMNH, antiviral). Physicochemical investigation of the SUL·AMNH salt revealed enhanced thermal stability compared to pristine starting materials. In vitro studies found that salt formation in SUL·AMNH does not disrupt antibacterial activity against model organisms Escherichia coli and Staphylococcus epidermidis. To our knowledge, we show the first β-lactamase inhibitor-antiviral salt where both components have been approved by the U.S. Food and Drug Administration (FDA), and the first multicomponent solid containing SUL. We envisage our strategy could inspire the design of multicomponent solids for antimicrobial combination therapies.
Rights
Copyright (c) 2025 The Authors
This work is licensed under a Creative Commons Attribution 4.0 International License.
Locate the Document
DOI
10.1039/d4pm00247d
Persistent Identifier
https://archives.pdx.edu/ds/psu/44055
Publisher
Royal Society of Chemistry (RSC)
Citation Details
Bicknell, J., Bondarenko, I., Colatrella, A., Cabrera-Vega, E. J., Loya, J. D., Botes, D. S., Mellies, J. L., & Campillo-Alvarado, G. (2024). Increased thermal stability and retained antibacterial properties in a sulbactam and amantadine salt: towards effective antibacterial–antiviral combination therapies. RSC Pharmaceutics, 1(5), 958–962.